Key facts
- Everbright Group is selling its healthcare unit, Cachet Pharmaceutical Co. Ltd.
- The sale price is approximately 1.5 billion yuan ($222 million).
- Beijing Tongrentang (Group) Co. Ltd. is the buyer.
- Cachet Pharmaceutical Co. Ltd. is Everbright Group's only listed healthcare unit.
- The unit has experienced years of declining earnings.
- The sale occurs amid an anti-corruption probe in China's medical sector.
China Everbright Group is divesting its sole listed healthcare entity, Cachet Pharmaceutical Co. Ltd., in a deal valued at approximately 1.5 billion yuan, which equates to $222 million USD. The buyer is Beijing Tongrentang (Group) Co. Ltd., a prominent traditional Chinese medicine producer. This strategic sale comes after Cachet Pharmaceutical experienced several years of diminishing financial returns. Furthermore, the transaction takes place within the context of an intensified anti-corruption campaign in China that has been specifically targeting the healthcare and medical sectors. The sale of Cachet Pharmaceutical is a notable development for Everbright Group, signaling a response to both internal financial strains and external regulatory pressures. The company's decision to sell its healthcare arm suggests a broader strategic realignment or a need to address financial challenges. The ongoing graft probe in the medical field has led to increased scrutiny of pharmaceutical companies and their operations, potentially impacting their valuations and future prospects. Everbright's move to offload this unit could be a proactive measure to mitigate risks associated with this regulatory environment and to improve its overall financial standing.